Full Breakdown
Trump Administration’s Secretive Pharma Deals Raise Transparency Concerns
By Drooid · · How we work
Core Event
Documents obtained by the consumer-advocacy group Public Citizen through a Freedom of Information Act request reveal that the Trump administration’s “most-favored-nation” (MFN) drug-pricing initiative includes undisclosed benefits for pharmaceutical companies. The agreements allow firms such as Eli Lilly to carve out its blockbuster GLP-1 drugs Mounjaro and Zepbound from MFN discount requirements, and a similar carve-out for Novo Nordisk could cut projected Medicaid savings by roughly $1.7 billion. Public Citizen also notes that Eli Lilly may stop supplying a medicine to another country under certain conditions, a provision that could keep foreign prices out of the MFN calculation and enable higher U.S. prices. Additional undisclosed tariff exemptions and expedited FDA review incentives are reported but not detailed in the released files.
Background & Context
The MFN program, promoted by President Donald Trump, invites all 50 states, Washington, DC, and Puerto Rico to join a Medicaid scheme that obliges participating manufacturers to price certain drugs at levels comparable to those in other wealthy nations. The administration has presented the initiative as a major step toward lowering prescription-drug costs for American patients.
Official Statements & Responses
President Trump continues to tout the MFN initiative as a breakthrough in drug-pricing reform. Health and Human Services Secretary Robert F. Kennedy Jr. previously pledged to make the agreements public, a promise that critics say remains unfulfilled. In August, Senator Elizabeth Warren (D-Mass.) publicly accused the administration of withholding the contracts, stating that “still crickets.”
Verbatim Quotes
- “Trump’s drug pricing deals are a mirage, designed to convince Americans that he’s taken significant action on drug pricing while creating minimal, if any, downside for Big Pharma,” — Peter Maybarduk, director of Public Citizen’s Access to Medicines program
- “The Trump administration continues to favor secrecy in these limited disclosures under FOIA today,” — Peter Maybarduk, director of Public Citizen’s Access to Medicines program
